期刊
CURRENT OPINION IN OPHTHALMOLOGY
卷 33, 期 3, 页码 167-173出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICU.0000000000000849
关键词
antivascular endothelial growth factor; brolucizumab; diabetic macular edema
Brolucizumab shows superior anatomical outcomes in treating DME and reduces treatment burden, but poses a risk for intraocular inflammation.
Purpose of review To review the available data supporting the use of brolucizumab in the treatment of diabetic macular edema (DME). Recent findings Brolucizumab is a humanized single- chain variable antibody fragment (scFv), the smallest functional subunit of an antibody approved for intravitreal use. Three phase III studies demonstrate that at 52 weeks, brolucizumab has statistically superior anatomical outcomes of reducing retinal thickness (54.0-57.5% of brolucizumab treated eyes achieved central subfield thickness <280 mu m compared to 40.1 - 41.4% of aflibercept treated eyes) and retinal fluid (present in 54.2-60.3% of brolucizumab treated eyes compared to 72.9-78.2% of aflibercept treated eyes). Brolucizumab also demonstrated a prolonged durability up to 16 weeks, thus reducing treatment burden. The visual outcomes appear noninferior to current anti-VEGF agents with an increased risk for intraocular inflammatory events (0.3-4.7% compared to 0.6-1.7%). Results from recent phase III trials showing the efficacy and safety of brolucizumab presents an additional therapeutic option in the DME treatment landscape. It can reduce treatment burden in DME with increased inter-treatment intervals while conferring efficacy in both functional and anatomical outcomes. Caution should be taken regarding the risks of intraocular inflammation, retinal vasculitis, and retinal vascular occlusion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据